NRX Pharmaceuticals (NRXP) Interest Expenses (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Interest Expenses of $233000.0 for Q1 2026, down 21.55% quarter-over-quarter from $297000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Interest Expenses (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Interest Expenses for 9 consecutive years, with $233000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses changed N/A year-over-year to $233000.0; the TTM figure through Mar 2026 stood at $530000.0 (up 130.43% YoY), while the FY2025 annual figure was $51.2 million, up 3.09% from the prior year.
- Interest Expenses fell to $233000.0 in Q1 2026 per NRXP's latest filing, from $297000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $2.5 million in Q4 2022 and bottomed at -$144000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $447000.0 across 5 years, with a median of $233000.0 in 2026.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 127350.0% — and 2024, when it sank 177.84%.
- NRX Pharmaceuticals' Interest Expenses stood at $2.5 million in 2022, then slumped by 92.74% to $185000.0 in 2023, then tumbled by 177.84% to -$144000.0 in 2024, then jumped by 306.25% to $297000.0 in 2025, then dropped by 21.55% to $233000.0 in 2026.
- Business Quant data shows NRXP's Interest Expenses at $233000.0 in Q1 2026, $297000.0 in Q4 2025, and $189000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 240,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 233,000.00 |
| Mar 31, 2026 | 233,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Dec 31, 2024 | -144,000.00 |
| Dec 31, 2024 | -144,000.00 |
| Mar 31, 2024 | 374,000.00 |
| Mar 31, 2024 | 374,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 46,000.00 |
| Mar 31, 2023 | 124,000.00 |
| Mar 31, 2023 | 124,000.00 |
| Dec 31, 2022 | 2.55 Mn |
| Dec 31, 2022 | 2.55 Mn |